How Canada's Updates to Clinical Trial Processes Are Shaping New Regulatory Standards by Yewande Oduwole
For sponsors running clinical trials in Canada, regulatory affairs has long been measured by a familiar set of expectations and milestones: a clean clinical trial application, a Notice of No Objection (NNO), amendments and notifications filed on time, and inspection records that hold up under review. That work remains essential.
Biomarker Strategies to Enhance Early-Phase Drug Development
Selecting the right biomarkers early in drug development can provide critical insights into drug activity, safety, and therapeutic response. By integrating biomarker strategies into early-phase studies, sponsors can optimize study design, support patient selection, demonstrate target engagement, and make more informed go/no-go decisions.
What You'll Learn:
- Key biomarker categories and their roles in assessing drug response, safety, and efficacy.
- Disease-specific biomarker strategies for CNS disorders, immuno-oncology, ophthalmology, and metabolic diseases.
- Biomarker considerations across therapeutic modalities, including small molecules, large molecules, and cell and gene therapies.
- Best practices for biomarker selection and fit-for-purpose validation to support reliable data and regulatory requirements.
- How integrated biomarker strategies, bioanalysis, and clinical expertise can support more efficient studies and confident development decisions.
Biomarkers by Disease Indication
Different treatments may require distinct biomarkers when the therapy acts on a unique biological mechanism, target, or pathway. Selecting the appropriate biomarker for your program is essential for robust data collection and analysis.
Multiplex biomarker panels allow for measurement of multiple proteins, cytokines, or metabolites from a single biological sample. These panels accelerate programs by providing comprehensive, multi-pathway insights into target engagement, PD, and early toxicity.
Development of an Investigational Epigenetic Silencer Therapy to Transcriptionally Inactivate Viral DNA in Chronic Hepatitis B
Endpoints News: The Patent Clock Is Already Running. Why Development Speed Is Also a Commercial Strategy
Pharmacokinetics and Analgesic Efficacy of Long-Acting Transdermal Buprenorphine in Miniature Swine
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials
Laval, Québec, September 24, 2026— Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began.
"The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these patients are treated. Altasciences has been an exceptional partner in our FDA journey.
Their ability to support us through drug product development and manufacturing, regulatory preparation, and now our Phase I clinical study has provided exactly the kind of integrated partnership an emerging pharmaceutical company needs. Reaching the Phase I clinical trial stage is an important milestone for RhineX, and Altasciences has been integral to 4B reaching this milestone.”
RhineX is a first-in-class medicated nasal rinse platform, with patents both approved and pending, designed to deliver medication throughout the nasal cavity and provide a simpler approach to steroid nasal irrigation for patients and healthcare providers. 4B is developing the therapeutic for patients with allergic rhinitis and chronic sinusitis, building on the use of steroid rinses in ENT and allergy practice.
The collaboration focused on developing and optimizing low- and high-dose steroid formulations for a 4B-patented sachet designed for nasal irrigation. Altasciences developed and evaluated multiple prototype formulations using innovative approaches and techniques, then manufactured R&D batches and packaged them into the 4B-proprietary sachets for testing.
The program also included analytical method development and qualification, accelerated stability testing, packaging evaluation, CMC consulting, including support for specification setting, and cGMP and quality assurance support to help advance the selected formulation toward clinical use.
“We’re proud to see the work completed by our Harleysville team help move RhineX into the clinic,” said Robert Sabelli, President, Drug Development Solutions at Altasciences. “This is where an integrated development model can make a real difference, allowing a program to move from formulation and manufacturing into clinical and bioanalytical execution with continuity across teams. We look forward to continuing to support 4B as RhineX advances.”
The Phase I clinical study will be conducted at Altasciences’ site in Los Angeles, CA, with bioanalytical support from its laboratory in Greater Montréal, QC, and broader CRO services supporting the program.
About Altasciences
Altasciences is a drug development organization dedicated to safely accelerating early-phase development for biotech, biopharmaceutical, and pharmaceutical companies. By combining the scale and expertise of a large CRO/CDMO with the flexibility and personalized approach of a mid-size partner, Altasciences delivers unified solutions across nonclinical, clinical, bioanalytical, and formulation and manufacturing services. Through intentional integration and true collaboration, the company removes barriers from lead candidate selection to clinical proof-of-concept—helping sponsors save time, reduce complexity, and make confident, data-driven decisions that enable earlier returns on investment. Guided by over 30 years of experience and a commitment to quality, integrity, and partnership, Altasciences enables clients to reach critical milestones faster and with greater confidence.
Accelerating Decision-Ready Hepatic PK Data: Adaptive Strategy and Integrated Execution Deliver LPE 19 Days Early
